TARS logo

Tarsus Pharmaceuticals, Inc. (TARS) Current Liabilities

Annual Current Liabilities:

$80.61M+$43.68M(+118.25%)
December 31, 2024

Summary

  • As of today, TARS annual current liabilities is $80.61 million, with the most recent change of +$43.68 million (+118.25%) on December 31, 2024.
  • During the last 3 years, TARS annual current liabilities has risen by +$69.13 million (+602.32%).
  • TARS annual current liabilities is now at all-time high.

Performance

TARS Current Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSbalance sheet metrics

Quarterly Current Liabilities:

$90.25M+$3.94M(+4.57%)
June 30, 2025

Summary

  • As of today, TARS quarterly current liabilities is $90.25 million, with the most recent change of +$3.94 million (+4.57%) on June 30, 2025.
  • Over the past year, TARS quarterly current liabilities has increased by +$38.68 million (+75.01%).
  • TARS quarterly current liabilities is now at all-time high.

Performance

TARS Quarterly Current Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSbalance sheet metrics

Current Liabilities Formula

Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities

TARS Current Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year+118.3%+75.0%
3Y3 Years+602.3%+670.2%
5Y5 Years+9742.7%+2835.1%

TARS Current Liabilities Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Yearat high+602.3%at high+580.9%
5Y5-Yearat high+9742.7%at high+1575.4%
All-TimeAll-Timeat high>+9999.0%at high>+9999.0%

TARS Current Liabilities History

DateAnnualQuarterly
Jun 2025
-
$90.25M(+4.6%)
Mar 2025
-
$86.31M(+7.1%)
Dec 2024
$80.61M(+118.2%)
$80.61M(+22.4%)
Sep 2024
-
$65.87M(+27.7%)
Jun 2024
-
$51.57M(+21.3%)
Mar 2024
-
$42.53M(+15.1%)
Dec 2023
$36.94M(+139.4%)
$36.94M(+58.9%)
Sep 2023
-
$23.25M(+57.5%)
Jun 2023
-
$14.77M(+11.4%)
Mar 2023
-
$13.26M(-14.1%)
Dec 2022
$15.43M
$15.43M(+8.1%)
DateAnnualQuarterly
Sep 2022
-
$14.27M(+21.8%)
Jun 2022
-
$11.72M(-7.1%)
Mar 2022
-
$12.61M(+9.9%)
Dec 2021
$11.48M(+113.1%)
$11.48M(+10.7%)
Sep 2021
-
$10.37M(-0.9%)
Jun 2021
-
$10.46M(+3.3%)
Mar 2021
-
$10.12M(+87.8%)
Dec 2020
$5.39M(+557.8%)
$5.39M(-12.3%)
Sep 2020
-
$6.14M(+99.8%)
Jun 2020
-
$3.08M(+275.5%)
Dec 2019
$819.00K(+357.5%)
$819.00K
Dec 2018
$179.00K
-

FAQ

  • What is Tarsus Pharmaceuticals, Inc. annual current liabilities?
  • What is the all-time high annual current liabilities for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. annual current liabilities year-on-year change?
  • What is Tarsus Pharmaceuticals, Inc. quarterly current liabilities?
  • What is the all-time high quarterly current liabilities for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. quarterly current liabilities year-on-year change?

What is Tarsus Pharmaceuticals, Inc. annual current liabilities?

The current annual current liabilities of TARS is $80.61M

What is the all-time high annual current liabilities for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high annual current liabilities is $80.61M

What is Tarsus Pharmaceuticals, Inc. annual current liabilities year-on-year change?

Over the past year, TARS annual current liabilities has changed by +$43.68M (+118.25%)

What is Tarsus Pharmaceuticals, Inc. quarterly current liabilities?

The current quarterly current liabilities of TARS is $90.25M

What is the all-time high quarterly current liabilities for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high quarterly current liabilities is $90.25M

What is Tarsus Pharmaceuticals, Inc. quarterly current liabilities year-on-year change?

Over the past year, TARS quarterly current liabilities has changed by +$38.68M (+75.01%)
On this page